Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.50)
# 913
Out of 5,090 analysts
13
Total ratings
72.73%
Success rate
15.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $33.22 | +92.66% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $9.42 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $40.50 | +13.58% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $18.63 | +28.82% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $6.23 | +333.39% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.24 | +819.81% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.31 | +83.99% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $10.91 | +110.82% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $26.42 | +74.11% | 1 | Sep 19, 2024 |
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $33.22
Upside: +92.66%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $9.42
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $40.50
Upside: +13.58%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $18.63
Upside: +28.82%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $6.23
Upside: +333.39%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.24
Upside: +819.81%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.31
Upside: +83.99%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $10.91
Upside: +110.82%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $26.42
Upside: +74.11%